About: High-dose therapy and autologous transplantation in poor prognosis patients with diffuse large B-cell lymphoma in first remission     Goto   Sponge   NotDistinct   Permalink

An Entity of Type : http://linked.opendata.cz/ontology/domain/vavai/Vysledek, within Data Space : linked.opendata.cz associated with source document(s)

AttributesValues
rdf:type
Description
  • Pacienti s vysoce rizikovým Difuzním velkobuněčným lymfomem (DLBCL) mohou profitovat s léčby vysoce dávkovanou chemoterapií (HDT) následovanou autologní transplantací kostní dřeně (ASCT). Hodnotili jsme soubor 55 pacientů s DLBCL léčených HDT a ASCT v období od března 1999 až do července 2006. Po indukční chemoterapii s rituximabem (44%) nebo bez imunoterapie (56%), 36 pacientů (65%) dosáhlo parciální remise a 19 pacientů (35%) kompletní remise. Po následné autologní transplantaci kostní dřeně splnilo kriteria kompletní remise 69% pacientů, 22% pacientů jsme hodnotili jako nejistou kompletní remisi, 7% pacientů zůstalo v parciální remisi a 1 pacient (2%) zrelaboval. Celkové přežití 55 transplantovaných pacientů v 5 letech je 85% a přežití bez případu je 76%. Tyto výsledky ukazují, že léčba rizikových pacientů s Difuzním velkobuněčným lymfomem do 65 let vysoce dávkovanou chemoterapií následovanou autologní transplantací kostní dřeně v 1. linii představuje efektivní terapeutický přístup. (cs)
  • Introduction: Improved survival has been observed in poor-risk diffuse large B-cell lymphoma (DLBCL) patients when treated with high-dose chemotherapy followed autologous transplantation (ASCT). Materials and Methods: We evaluated the results of HDT and ASCT in 55 patients treated between May 1999 and July 2006 with confimed DLBCL. Results: 36 patients (65%) had a partial response (PR) and 19 patiennts (35%) reached a complete remission (CR) after induction treatment with (44%) or without (56%) concomitant rituximab ? immunotherapy. After HDT and ASCT 69% patients fulfilled the criteria of CR, 22% patients ahd and unconfirmedCR (Cru), 7% patients were still only in PR and 1 patient (2%) relapsed. The 5-year event-free survival (EFS) of the 55 transplanted patients was 76% and the 5-year overall survival (OS) was 85%. EFS and OS rates differed significantly only between patients younger than 40 years and older groups (p=0.022 and p=0.046, respectively). Conclusion: These results shows that first-li
  • Introduction: Improved survival has been observed in poor-risk diffuse large B-cell lymphoma (DLBCL) patients when treated with high-dose chemotherapy followed autologous transplantation (ASCT). Materials and Methods: We evaluated the results of HDT and ASCT in 55 patients treated between May 1999 and July 2006 with confimed DLBCL. Results: 36 patients (65%) had a partial response (PR) and 19 patiennts (35%) reached a complete remission (CR) after induction treatment with (44%) or without (56%) concomitant rituximab ? immunotherapy. After HDT and ASCT 69% patients fulfilled the criteria of CR, 22% patients ahd and unconfirmedCR (Cru), 7% patients were still only in PR and 1 patient (2%) relapsed. The 5-year event-free survival (EFS) of the 55 transplanted patients was 76% and the 5-year overall survival (OS) was 85%. EFS and OS rates differed significantly only between patients younger than 40 years and older groups (p=0.022 and p=0.046, respectively). Conclusion: These results shows that first-li (en)
Title
  • High-dose therapy and autologous transplantation in poor prognosis patients with diffuse large B-cell lymphoma in first remission
  • Vysoce dávkovaná chemoterapie a autologní transplantace u pacientů s rizikovým Difuzním velkobuněčným B lymfomem v 1. remisi (cs)
  • High-dose therapy and autologous transplantation in poor prognosis patients with diffuse large B-cell lymphoma in first remission (en)
skos:prefLabel
  • High-dose therapy and autologous transplantation in poor prognosis patients with diffuse large B-cell lymphoma in first remission
  • Vysoce dávkovaná chemoterapie a autologní transplantace u pacientů s rizikovým Difuzním velkobuněčným B lymfomem v 1. remisi (cs)
  • High-dose therapy and autologous transplantation in poor prognosis patients with diffuse large B-cell lymphoma in first remission (en)
skos:notation
  • RIV/61989592:15110/07:00004380!RIV08-MSM-15110___
http://linked.open.../vavai/riv/strany
  • 93
http://linked.open...avai/riv/aktivita
http://linked.open...avai/riv/aktivity
  • Z(MSM6198959205)
http://linked.open...iv/cisloPeriodika
  • S1
http://linked.open...vai/riv/dodaniDat
http://linked.open...aciTvurceVysledku
http://linked.open.../riv/druhVysledku
http://linked.open...iv/duvernostUdaju
http://linked.open...titaPredkladatele
http://linked.open...dnocenehoVysledku
  • 424114
http://linked.open...ai/riv/idVysledku
  • RIV/61989592:15110/07:00004380
http://linked.open...riv/jazykVysledku
http://linked.open.../riv/klicovaSlova
  • large B-cell lymphoma; autolous transplantation (en)
http://linked.open.../riv/klicoveSlovo
http://linked.open...odStatuVydavatele
  • GB - Spojené království Velké Británie a Severního Irska
http://linked.open...ontrolniKodProRIV
  • [B685752A2424]
http://linked.open...i/riv/nazevZdroje
  • Blood reviews
http://linked.open...in/vavai/riv/obor
http://linked.open...ichTvurcuVysledku
http://linked.open...cetTvurcuVysledku
http://linked.open...UplatneniVysledku
http://linked.open...v/svazekPeriodika
  • 21
http://linked.open...iv/tvurceVysledku
  • Dušek, Ladislav
  • Faber, Edgar
  • Indrák, Karel
  • Jarkovský, J.
  • Jarošová, Marie
  • Kubová, Zuzana
  • Raida, Luděk
  • Skoumalová, Ivana
  • Vondráková, Jana
  • Procházka, Vít
  • Papajík, Tomáš
http://linked.open...n/vavai/riv/zamer
issn
  • 0268-960X
number of pages
http://localhost/t...ganizacniJednotka
  • 15110
Faceted Search & Find service v1.16.118 as of Jun 21 2024


Alternative Linked Data Documents: ODE     Content Formats:   [cxml] [csv]     RDF   [text] [turtle] [ld+json] [rdf+json] [rdf+xml]     ODATA   [atom+xml] [odata+json]     Microdata   [microdata+json] [html]    About   
This material is Open Knowledge   W3C Semantic Web Technology [RDF Data] Valid XHTML + RDFa
OpenLink Virtuoso version 07.20.3240 as of Jun 21 2024, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (126 GB total memory, 82 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software